Enrique Grande Pulido-rekin lankidetzan egindako argitalpenak (24)

2024

  1. Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)

    Nature Communications, Vol. 15, Núm. 1

2023

  1. SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2692-2706

  2. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

    European Journal of Cancer, Vol. 188, pp. 39-48

2022

  1. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors

    Journal of Neuroendocrinology, Vol. 34, Núm. 3

  2. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  3. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

    The oncologist, Vol. 27, Núm. 4, pp. e328-e339

  4. Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

    Neuroendocrinology, Vol. 112, Núm. 12, pp. 1155-1167

2021

  1. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

  2. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial

    Oncologist, Vol. 26, Núm. 11, pp. 941-949

2020

  1. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    Oncologist, Vol. 25, Núm. 9, pp. 745-e1265

2019

  1. Economics of gastroenteropancreatic neuroendocrine tumors: a systematic review

    Therapeutic Advances in Endocrinology and Metabolism, Vol. 10

  2. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

  3. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  4. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2018

  1. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors

    Oncologist, Vol. 23, Núm. 7, pp. 766-e90

  2. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

    Cancer Treatment Reviews, Vol. 70, pp. 209-222

2017

  1. Optimizing somatostatin analog use in well or moderately differentiated gastroenteropancreatic neuroendocrine tumors

    Current Oncology Reports, Vol. 19, Núm. 11

  2. Translational research in neuroendocrine tumors: Pitfalls and opportunities

    Oncogene, Vol. 36, Núm. 14, pp. 1899-1907

2016

  1. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: Results of a Delphi questionnaire panel from the NETPraxis program

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors

    Cancer and Metastasis Reviews, Vol. 34, Núm. 3, pp. 381-400